var data={"title":"Omeprazole: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Omeprazole: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6682?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">see &quot;Omeprazole: Drug information&quot;</a> and <a href=\"topic.htm?path=omeprazole-patient-drug-information\" class=\"drug drug_patient\">see &quot;Omeprazole: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50836889\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Proton Pump Inhibitors Safety Alert</span>\n      <span class=\"collapsible-date\">December 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has issued a safety alert regarding the rare risk of subacute cutaneous lupus erythematosus with the use of proton pump inhibitors (PPI). This alert was prompted following a published article that examined reports in the FDA Adverse Event Reporting System.</p>\n        <p style=\"text-indent:0em;\">Health Canada is working with manufacturers to update the safety information to include these findings in all PPI-containing products. More information may be found at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/safety-reviews/proton-pump-inhibitors-assessing-risk-type-skin-reaction.html.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203557\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>First-Omeprazole;</li>\n      <li>Omeprazole+Syrspend SF Alka;</li>\n      <li>PriLOSEC;</li>\n      <li>PriLOSEC OTC [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203558\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Omeprazole;</li>\n      <li>Auro-Omeprazole;</li>\n      <li>Dom-Omeprazole DR;</li>\n      <li>JAMP-Omeprazole DR;</li>\n      <li>Losec;</li>\n      <li>Mylan-Omeprazole;</li>\n      <li>Olex;</li>\n      <li>PMS-Omeprazole;</li>\n      <li>PMS-Omeprazole DR;</li>\n      <li>Q-Omeprazole;</li>\n      <li>RAN-Omeprazole;</li>\n      <li>ratio-Omeprazole;</li>\n      <li>Riva-Omeprazole DR;</li>\n      <li>Sandoz-Omeprazole;</li>\n      <li>Teva-Omeprazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060710\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastric Acid Secretion Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Proton Pump Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27749095\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>GERD:</b> Oral: 0.7 mg/kg/dose once daily reduced the percentage of time gastric and esophageal pH &lt;4, as well as the number of reflux episodes in 10 infants (mean PMA: 36.1 weeks; range: 34 to 40 weeks) in a double-blind, placebo-controlled trial (Omari 2007); higher doses of 1 to 1.5 mg/kg/day have been reported (Gibbons 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060704\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">see &quot;Omeprazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Erosive esophagitis, treatment (short-term):</b> Oral: Infants, Children, and Adolescents: <b>Note:</b> Duration of therapy for infants is up to 6 weeks. The duration of therapy for children and adolescents is up to 4 to 8 weeks; may continue for an additional 4 weeks if no response to 8 weeks of treatment; with recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), an additional 4 to 8 week course may be considered</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;5 kg: 2.5 mg once daily  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">5 kg to &lt;10 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">10 kg to &lt;20 kg: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;20 kg: 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Erosive esophagitis, maintenance of healing:</b> Children and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">5 kg to &lt;10 kg: 5 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">10 kg to &lt;20 kg: 10 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">&ge;20 kg: 20 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>GERD:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants: 0.7 mg/kg/dose once daily reduced the percentage of time gastric and esophageal pH &lt;4, as well as the number of reflux episodes in 10 infants [mean PMA: 36.1 weeks (34 to 40 weeks)] in a double-blind, placebo-controlled trial (Omari 2007); higher doses of 1 to 1.5 mg/kg/day have been reported (Gibbons 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">5 kg to &lt;10 kg: 5 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">10 kg to &lt;20 kg: 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">&ge;20 kg: 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">Alternate dosing: Infants, Children, and Adolescents: 0.7 to 3.3 mg/kg/day; maximum daily dose: 20 mg/<b>day</b>; the dose most frequently reported to provide healing of esophagitis and relief of GERD symptoms is 1 mg/kg/day (Lightdale 2013; Zimmerman 2001). In critically ill children to maintain gastric pH &gt;5, administration every 6 to 8 hours may be necessary (1.5 to 2 mg/kg/day) (Kaufman 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Helicobacter pylori</i> eradication:</b> Oral: Children and Adolescents:  <b>Note:</b> Usual duration of therapy is 7 to 14 days; use in combination with antimicrobials (eg, clarithromycin, metronidazole, amoxicillin).    </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Weight-based: 1 to 2 mg/kg/day divided into 2 doses; maximum single dose: 20 mg (Gold 2000; Koletzko 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Fixed dosing (Gottrand 2001):  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">15 to 30 kg: 10 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">&gt;30 kg: 20 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Duodenal ulcer:</b> Oral: 20 mg once daily for 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Gastric ulcers:</b> Oral: 40 mg once daily for 4 to 8 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>GERD, symptomatic:</b> Oral: 20 mg once daily for up to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Erosive esophagitis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Treatment:</i> 20 mg once daily for 4 to 8 weeks; may continue for an additional 4 weeks if no response to 8 weeks of treatment. With recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), an additional 4 to 8 weeks of treatment may be considered.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Maintenance of healing:</i> 20 mg once daily (studies did not extend beyond 12 months); 10 mg once daily is recommended for Asian patients</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>\n        <i>Helicobacter pylori</i> eradication:</b> Oral: Dose varies with regimen: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Dual therapy:</i> 40 mg once daily administered with clarithromycin for 14 days. In patients with presence of ulcer at time of therapy initiation, continue omeprazole 20 mg once daily for an additional 14 days after completion of dual therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">\n      <i>Triple therapy:</i> 20 mg twice daily administered with amoxicillin and clarithromycin twice daily for 10 days. In patients with presence of ulcer at time of therapy initiation, continue omeprazole 20 mg once daily for an additional 18 days after completion of triple therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Pathological hypersecretory conditions:</b> Oral: Initial: 60 mg once daily; doses up to 120 mg 3 times daily have been administered; administer daily doses &gt;80 mg in divided doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <b>Frequent heartburn (OTC labeling):</b> Oral: 20 mg once daily for 14 days; treatment may be repeated after 4 months if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in renal impairment:</b> Infants, Children, Adolescents, and Adults: No dosage adjustments are recommended</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Infants, Children, Adolescents, and Adults: There are no dosage adjustments provided in the manufacturer's labeling. However, based on increased bioavailability, dosage adjustment should be considered, especially for maintenance healing of erosive esophagitis. Specific guidelines are not available.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203531\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PriLOSEC: 10 mg [DSC], 20 mg [DSC], 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Delayed Release, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PriLOSEC: 2.5 mg (30 ea); 10 mg (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">First-Omeprazole: 2 mg/mL (90 mL, 150 mL, 300 mL) [contains benzyl alcohol, fd&amp;c red #40, saccharin sodium; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omeprazole+Syrspend SF Alka: 2 mg/mL (120 mL, 240 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Omeprazole+Syrspend SF Alka: 2 mg/mL (100 mL) [cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Delayed Release, Oral, as magnesium [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PriLOSEC OTC: 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PriLOSEC OTC: 20 mg [contains fd&amp;c blue #2 aluminum lake, fd&amp;c red #40 aluminum lake, saccharin sodium; wild berry flavor]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203517\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45040042\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">see &quot;Omeprazole: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">First-Omeprazole and Omeprazole+Syrspend SF Alka oral suspensions are compounding kits. Refer to manufacturer&rsquo;s labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15241703\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">Prilosec capsules, granules for oral suspension: <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM322359.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9BK5et6GehFK9IioulPK5W0MuiIDHX6eB0jXwuMVnHtg==&amp;TOPIC_ID=12658\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM322359.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060713\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Should be taken before meals; best if taken 30 minutes before a meal (Lightdale 2013); may be administered with antacids</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: Should be swallowed whole; do not chew or crush. Delayed release capsule may be opened and contents added to 1 tablespoon of applesauce; use immediately after adding to applesauce; do not chew. Follow with a cool glass of water. Applesauce should not be heated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Empty the contents of the 2.5 mg packet or 10 mg packet into 5 mL or 15 mL of water, respectively; stir, the suspension should be left to thicken for 2 to 3 minutes and administered within 30 minutes. If any material remains after administration, add more water, stir, and administer immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Should be swallowed whole; do not crush or chew.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nasogastric tube administration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule: The manufacturer of Prilosec does not give recommendations for extemporaneous preparation of omeprazole capsules for NG/OG administration. Consider using the packets for oral suspension. If packets are unavailable, methods of preparation of capsules for NG/OG administration have been described (Balaban 1997; Phillips 1996). An extemporaneously prepared suspension with extended stability may also be used (DiGiacinto 2000; Quercia 1997; Sharma 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral suspension: Add 5 mL of water to a catheter-tipped syringe and then add the contents of a 2.5 mg packet (or 15 mL of water for the 10 mg packet), shake the suspension well and leave to thicken for 2 to 3 minutes. Administer within 30 minutes of reconstitution. Use an NG or gastric tube that is a French size 6 or larger; refill syringe with an equal amount of water, shake, and flush remaining contents through NG or gastric tube.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203552\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules, tablets: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light and moisture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Granules for oral suspension: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for suspension (compounding kits): Refer to manufacturer's labeling. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC capsules: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from moisture. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060712\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Short-term treatment (4 to 8 weeks) of severe erosive esophagitis (FDA approved in ages &ge;1 month and adults); maintenance of healing of erosive esophagitis (FDA approved in ages &ge;1 year and adults); treatment of symptomatic gastroesophageal reflux disease (GERD) (FDA approved in ages &ge;1 year and adults); short-term treatment (4 to 8 weeks) of active duodenal ulcers and active benign gastric ulcers (FDA approved in adults); adjunctive treatment of duodenal ulcers associated with <i>Helicobacter pylori</i> (FDA approved in adults); treatment of pathological hypersecretory conditions (FDA approved in adults); relief of frequent heartburn (OTC products; FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203615\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Omeprazole may be confused with aripiprazole, esomeprazole, fomepizole</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">PriLOSEC may be confused with Plendil, Prevacid, predniSONE, prilocaine, Prinivil, Pristiq, Proventil, PROzac</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Proton pump inhibitors (omeprazole) are identified in the Beers Criteria as potentially inappropriate medications to be avoided (as scheduled use for more than 8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection and bone loss/fractures. Use more than 8 weeks should be avoided <i>unless</i> given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett's esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Losec [multiple international markets] may be confused with Lasix brand name for furosemide [US, Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Medral [Mexico] may be confused with Medrol brand name for methylprednisolone [US., Canada, and multiple international markets]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Norpramin: Brand name for omeprazole [Spain], but also the brand name for desipramine [US, Canada] and enalapril/hydrochlorothiazide [Portugal]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Protonix: Brand name for omeprazole [Philippines] but also the brand name for pantoprazole [US]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203613\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, acid regurgitation, constipation, diarrhea, flatulence, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Back pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, upper respiratory infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal swelling, abnormal dreams, aggression, agitation, agranulocytosis, allergic reactions, alopecia, anaphylaxis, anemia, angina pectoris, angioedema, anorexia, anxiety, apathy, arthralgia, atrophic gastritis, blurred vision, bone fracture, bradycardia, bronchospasm, chest pain, cholestatic hepatitis, <i>Clostridium difficile</i>-associated diarrhea (CDAD), colitis (microscopic), confusion, cutaneous lupus erythematosus, depression, dermatitis, diplopia, disturbed sleep, drowsiness, dysgeusia, epistaxis, erythema multiforme, esophageal candidiasis, fatigue, fecal discoloration, fever, gastric carcinoid tumor, gastric polyp (benign), glycosuria, gynecomastia, hallucination, hematuria, hemolytic anemia, hepatic disease (hepatocellular, cholestatic, mixed), hepatic encephalopathy, hepatic failure, hepatic necrosis, hepatitis, hepatocellular hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2014), hyperhidrosis, hypersensitivity, hypertension, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, increased gamma glutamyl transferase, increased serum alkaline phosphatase, increased serum bilirubin, increased serum creatinine, increased serum transaminases, insomnia, interstitial nephritis, irritable bowel syndrome, jaundice, leg pain, leukocytosis, leukopenia, malaise, microscopic pyuria, mucosal atrophy (tongue), muscle cramps, myalgia, myasthenia, nervousness, neutropenia, ocular irritation, optic atrophy, optic neuritis, optic neuropathy (anterior ischemic), osteoporosis-related fracture, pain, palpitation, pancreatitis, pancytopenia, paresthesia, peripheral edema, petechiae, photophobia, pneumonia, proteinuria, pruritus, psychiatric disturbance, purpura, renal disease (chronic; Lazarus 2016), sore throat, Stevens-Johnson syndrome, stomatitis, systemic lupus erythematosus, tachycardia, testicular pain, thrombocytopenia, tinnitus, toxic epidermal necrolysis, tremor, urinary frequency, urinary tract infection, urticaria, vertigo, weight gain, xeroderma, xerophthalmia, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203539\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria) to omeprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; concomitant use with products that contain rilpivirine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication (OTC), do not use if trouble or pain when swallowing food; vomiting with blood, or bloody or black stools; heartburn with lightheadedness, dizziness, or sweating; chest pain or shoulder pain with shortness of breath, sweating, pain spreading to arms, neck or shoulders, or lightheadedness; frequent chest pain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203521\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Carcinoma: In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; <i>Clostridium difficile</i>-associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous and systemic lupus erythematosus: Has been reported as new onset or exacerbation of existing autoimmune disease; most cases were cutaneous lupus erythematosus (CLE), most commonly, subacute CLE (occurring within weeks to years after continuous therapy). Systemic lupus erythematosus (SLE) is less common (typically occurs within days to years after initiating treatment) and occurred primarily in young adults up to the elderly. Discontinue therapy if signs or symptoms of CLE or SLE occur and refer to specialist for evaluation; most patients improve 4 to 12 weeks after discontinuation of omeprazole.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose (multiple daily doses) or long-term (&ge;1 year) therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &ge;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter. Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of omeprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Interstitial nephritis: Acute interstitial nephritis has been observed in patients taking PPIs; may occur at any time during therapy and is generally due to an idiopathic hypersensitivity reaction. Discontinue if acute interstitial nephritis develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamin B<sub>12 </sub>deficiency: Prolonged treatment (&gt;3 years) may lead to vitamin B<sub>12 </sub> malabsorption and subsequent vitamin B<sub>12 </sub> deficiency. The magnitude of the deficiency is dose-related and the association is stronger in females and those younger in age (&lt;30 years); prevalence is decreased after discontinuation of therapy (Lam, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal infection (eg, <i>Salmonella, Campylobacter</i>): Use of PPIs may increase risk of these infections.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: In patients with hepatic impairment (Child-Pugh class A, B, or C) exposure to omeprazole is increased; dosage reduction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Asian ethnicity: Bioavailability is increased in patients of Asian descent; dosage reduction is recommended for maintenance healing of erosive esophagitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Bioavailability may be increased in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop omeprazole treatment at least 14 days before CgA test; if initial CgA levels are high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Self-medication (OTC use): When used for self-medication (OTC), notify health care provider before use if any of the following are present: heartburn for &gt;3 months; frequent wheezing, particularly with heartburn; unexplained weight loss; nausea or vomiting; or stomach pain. Discontinue use and notify health care provider if heartburn continues or worsens; diarrhea occurs; if &gt;14 days of therapy is needed; or if &gt;1 course of therapy is needed every 4 months.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203601\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2A6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak), CYP2C9 (moderate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203526\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12658&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: Proton Pump Inhibitors may decrease the serum concentration of Acalabrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamine: Proton Pump Inhibitors may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May decrease the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: See full drug interaction monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Bosentan.  Management: Concomitant use of both a CYP2C9 inhibitor and a CYP3A inhibitor or a single agent that inhibits both enzymes with bosentan is likely to cause a large increase in serum concentrations of bosentan and is not recommended.  See monograph for details.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Cannabis. More specifically, tetrahydrocannabinol serum concentrations may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capecitabine: Proton Pump Inhibitors may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefpodoxime: Proton Pump Inhibitors may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefuroxime: Proton Pump Inhibitors may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cilostazol: CYP2C19 Inhibitors may increase the serum concentration of Cilostazol.  Management: Consider reducing the cilostazol dose to 50 mg twice daily in patients who are also receiving inhibitors of CYP2C19.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: Omeprazole may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with omeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloBAZam: Omeprazole may increase serum concentrations of the active metabolite(s) of CloBAZam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Clopidogrel labeling recommends avoiding concurrent omeprazole due to a possible decrease in clopidogrel effectiveness. Rabeprazole or pantoprazole may be lower-risk alternatives to omeprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Omeprazole may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inhibitors): CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cysteamine (Systemic): Proton Pump Inhibitors may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP2C19 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: Proton Pump Inhibitors may decrease the serum concentration of Dabrafenib. Dabrafenib may decrease the serum concentration of Proton Pump Inhibitors.  Management: Seek alternatives to the proton pump inhibitor when possible.  If concomitant therapy cannot be avoided, monitor for diminished effects of both drugs.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May decrease the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextroamphetamine: Proton Pump Inhibitors may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers). Conversely, concentrations of active metabolites may be increased for those drugs activated by CYP2C19. Management: Concurrent use of enzalutamide with CYP2C19 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP2C19 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Escitalopram: Omeprazole may increase the serum concentration of Escitalopram.  Management: Monitor for increased escitalopram toxicity with concomitant use of omeprazole. Recommendations for management of this interaction found in product labeling may differ by country. Consult appropriate labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Omeprazole may increase the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.  Management: Avoid use of proton pump inhibitors (PPIs) with gefitinib when possible. If required, administer gefitinib 12 hours after administration of the PPI or 12 hours before the next dose of the PPI.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts. <b> Exceptions: </b>Ferric Carboxymaltose; Ferric Citrate; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: Proton Pump Inhibitors may decrease the serum concentration of Ledipasvir.  Management: PPI doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Administration with higher doses of PPIs, 2 hours after a PPI, or in combination with food and PPIs may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: Omeprazole may decrease the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: Proton Pump Inhibitors may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: Proton Pump Inhibitors may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May decrease the serum concentration of Omeprazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Riociguat: Proton Pump Inhibitors may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Proton Pump Inhibitors may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of proton pump inhibitors (PPIs) and secretin, and discontinue PPIs several weeks prior to secretin administration, with the duration of separation determined by the specific PPI. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of Omeprazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: Proton Pump Inhibitors may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Proton Pump Inhibitors. Proton Pump Inhibitors may increase the serum concentration of Voriconazole. Management: In patients receiving omeprazole 40 mg/day or greater, reduce omeprazole dose by half when initiating voriconazole.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203553\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Prolonged treatment (&ge;2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203542\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">An increased risk of hypospadias was reported following maternal use of proton pump inhibitors (PPIs) during pregnancy (Anderka 2012), but this was based on a small number of exposures and the same association was not found in another study (Erichsen 2012). Most available studies have not shown an increased risk of major birth defects following maternal use of omeprazole during pregnancy (Diav-Citrin 2005; K&auml;ll&eacute;n 2001; Lalkin 1998; Matok 2012; Pasternak 2010). When treating GERD in pregnancy, PPIs may be used when clinically indicated (ACT [Katz 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203520\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Proton pump inhibitor; suppresses gastric basal and stimulated acid secretion by inhibiting the parietal cell H+/K+ ATP pump</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203538\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Half-life and AUC were significantly reduced for omeprazole suspension when compared with an equivalent dose via the commercially available capsule in 7 adults (Song 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antisecretory: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: Within 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Up to 72 hours; 50% of maximum effect at 24 hours; after stopping treatment, secretory activity gradually returns over 3 to 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Maximum secretory inhibition: 4 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP2C19 primarily and (to a lesser extent) via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive); saturable first-pass effect</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: ~30% to 40%; Hepatic dysfunction: ~100%; Asians: AUC increased up to fourfold compared to Caucasians</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 0.5 to 1 hour; hepatic impairment: ~3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 0.5 to 3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~77% as metabolites, very small amount as unchanged drug); feces</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: 500-600 mL/minute; chronic hepatic disease: 70 mL/minute </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203537\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> More palatable omeprazole (2 mg/mL) suspensions are commercially available as compounding kits (First-Omeprazole, Omeprazole+Syrspend SF Alka Cherry Kit).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">A 2 mg/mL oral omeprazole solution (Simplified Omeprazole Solution) may be made with five omeprazole 20 mg delayed release capsules and 50 mL sodium bicarbonate 8.4%. Empty capsules into beaker. Add sodium bicarbonate solution. Gently stir (about 15 minutes) until a white suspension forms. Transfer to amber-colored syringe or bottle. Stable for 14 days at room temperature or for 30 days refrigerated.</p>\n    <div class=\"reference\">DiGiacinto JL, Olsen KM, Bergman KL, et al, &ldquo;Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes,&rdquo; <i>Ann Pharmacother</i>, 2000, 34(5):600-5. <span class=\"pubmed-id\">10852086</span></div>\r\n\n    <div class=\"reference\">Quercia R, Fan C, Liu X, et al, &ldquo;Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid,&rdquo; <i>Am J Health Syst Pharm</i>, 1997, 54(16):1833-6. <span class=\"pubmed-id\">9269520</span></div>\r\n\n    <div class=\"reference\">Sharma V, &ldquo;Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole,&rdquo; <i>Am J Health Syst Pharm</i>, 1999, 56(23 Suppl 4):18-21.<span class=\"pubmed-id\">10597120</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203541\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Omeprazole Magnesium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20.6 (20 Base) mg (14): $9.18</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, delayed release</b> (Omeprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $111.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $124.55</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $221.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (PriLOSEC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (30): $317.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $317.47</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (First-Omeprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (150 mL): $75.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Omeprazole+Syrspend SF Alka Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/mL (120 mL): $196.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (Omeprazole Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (28): $19.21</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, EC</b> (PriLOSEC OTC Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (28): $20.14</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203544\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acifre (PH);</li>\n      <li>Acimax (AU);</li>\n      <li>Aleprozil (MX);</li>\n      <li>Antra (AT, IT);</li>\n      <li>Arapride (ES);</li>\n      <li>Aulcer (ES);</li>\n      <li>Azoran (MX);</li>\n      <li>Benzol (MT);</li>\n      <li>Crismel (HU);</li>\n      <li>Desec (TH);</li>\n      <li>Domer (MX);</li>\n      <li>Dudencer (HK);</li>\n      <li>Duogas (TH);</li>\n      <li>Epirazole (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Eupept (BR);</li>\n      <li>Ezrazole (PH);</li>\n      <li>Gasec (BB, BM, BS, BZ, EC, GY, HK, JM, MY, SR, TT);</li>\n      <li>Gasec Gastrocaps (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Gastec (AR);</li>\n      <li>Gastop (PE);</li>\n      <li>Gastracid (DE);</li>\n      <li>Gastrofer (ID);</li>\n      <li>Getzone (VN);</li>\n      <li>Hasek (UA);</li>\n      <li>Healor (BD);</li>\n      <li>Helizol (EC);</li>\n      <li>Hyposec (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, SA, SY, YE);</li>\n      <li>Inhibitron (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Inhipump (ID);</li>\n      <li>Lensor (LU);</li>\n      <li>Locid (ET);</li>\n      <li>Logastric (BE);</li>\n      <li>Lokev (ID);</li>\n      <li>Lokit (ET);</li>\n      <li>Lomac (IN);</li>\n      <li>Lomex (PY);</li>\n      <li>Lopraz (IE);</li>\n      <li>Losamel (IE);</li>\n      <li>Losec (AE, AR, AT, AU, BB, BE, BF, BH, BJ, BM, BR, BS, BZ, CI, CN, CY, CZ, DK, EE, EG, ES, ET, FI, GB, GH, GM, GN, GR, GY, HK, HU, IE, IL, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NZ, OM, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SL, SN, SR, SY, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZM, ZW);</li>\n      <li>Losec MUPS (CO, MY, PH);</li>\n      <li>Loseprazol (SI);</li>\n      <li>Luodan (CN);</li>\n      <li>Madiprazole (TH);</li>\n      <li>Maxor (AU);</li>\n      <li>Medoprazole (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Mepha Gasec (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Mepracid (PH);</li>\n      <li>Meprazol (AU);</li>\n      <li>Miracid (TH);</li>\n      <li>Mopral (FR, MX);</li>\n      <li>Nocid (HK, TH);</li>\n      <li>Ocid (ET, IN, LK, SG);</li>\n      <li>Ogal (CO, PE);</li>\n      <li>Olexin (MX);</li>\n      <li>Olit (SG);</li>\n      <li>Om (BD);</li>\n      <li>Omed (BF, BJ, CH, CI, ET, GH, GM, GN, ID, IN, KE, KR, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Omedar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Omelon (MY, TW);</li>\n      <li>Omep (BD, HK);</li>\n      <li>OMEP (DE);</li>\n      <li>Omepra (IL);</li>\n      <li>Omepradex (IL);</li>\n      <li>Omepradex-Z (IL);</li>\n      <li>Omepral (AU, JP);</li>\n      <li>Omeprazon (JP);</li>\n      <li>Omepril (EC);</li>\n      <li>Omeq (KR);</li>\n      <li>Omesec (HK, MY, SG);</li>\n      <li>Omesel (VN);</li>\n      <li>Omex (CO);</li>\n      <li>Omez (VN);</li>\n      <li>Omezol (AE, BH, CY, EG, IN, IQ, IR, JO, KW, LB, LY, NZ, OM, SA, SY, YE);</li>\n      <li>Omezole (HK, SG, TW);</li>\n      <li>Omezzol (EC);</li>\n      <li>Omisec (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Omiz (QA);</li>\n      <li>Omizac (IN);</li>\n      <li>Omizec (HK);</li>\n      <li>OMP (KR);</li>\n      <li>Ompranyt (MT);</li>\n      <li>Omprazole (KR);</li>\n      <li>OMZ (ID);</li>\n      <li>Onic (ID);</li>\n      <li>Opal (PE);</li>\n      <li>Opel (PH);</li>\n      <li>Oprax (PE);</li>\n      <li>Oprazole (AE, BH, JO, KW, LB, QA, SA);</li>\n      <li>Orazole (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Ortanol (HR);</li>\n      <li>Ozmep (AU);</li>\n      <li>Ozol (UA);</li>\n      <li>Parizac (ES);</li>\n      <li>Penrazole (SG);</li>\n      <li>Peptaz (LK);</li>\n      <li>Peptizole (TH);</li>\n      <li>Prazidec (MX);</li>\n      <li>Prazole (TH);</li>\n      <li>Probitor (AU, BG, MY, SG);</li>\n      <li>Proceptin (SG);</li>\n      <li>Promezol (ID);</li>\n      <li>Proton (UA);</li>\n      <li>Protonix (PH);</li>\n      <li>Pumpitor (ID, LK, SG);</li>\n      <li>Pumpitor DI (ID);</li>\n      <li>Qrazol (KR);</li>\n      <li>Ramezol (KR);</li>\n      <li>Result (KR);</li>\n      <li>Risek (AE, BH, ET, JO, KW, LB, MY, PH, QA, SA);</li>\n      <li>Romep (IE);</li>\n      <li>Siozole (IN);</li>\n      <li>Stomacer (ID);</li>\n      <li>Stomec (TH);</li>\n      <li>Suifac (MX);</li>\n      <li>Trisec (LK);</li>\n      <li>Ulcozol (EC, PE);</li>\n      <li>Ulnor (DE);</li>\n      <li>Ulpraz (ID);</li>\n      <li>Ulsen (MX);</li>\n      <li>Ultop (HR, UA);</li>\n      <li>Ulzec (ZA);</li>\n      <li>Ulzol (ID);</li>\n      <li>Vescomecid (TH);</li>\n      <li>Viprazo (PH);</li>\n      <li>Vulcasid (MX);</li>\n      <li>Wonmp (KR);</li>\n      <li>Xeldrin (BD);</li>\n      <li>Xoprin (PE);</li>\n      <li>Zatrol (CL);</li>\n      <li>Zefxon (MY, TH);</li>\n      <li>Zenpro (MY, SG);</li>\n      <li>Zenprol (HK);</li>\n      <li>Zimor (MY, SG);</li>\n      <li>Ziom (LK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abraham NS, Hlatky MA, Antman EM, et al, &quot;CCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&quot; <i>Circulation</i>, 2010, 122(24):2619-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21060077/pubmed\" target=\"_blank\" id=\"21060077\">21060077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderka M, Mitchell AA, Louik C, et al, &quot;Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22102545/pubmed\" target=\"_blank\" id=\"22102545\">22102545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersson T, Hassall E, Lundborg P, et al, &quot;Pharmacokinetics of Orally Administered Omeprazole in Children. International Pediatric Omeprazole Pharmacokinetic Group,&quot; <i>Am J Gastroenterol</i>, 2000, 95(11):3101-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11095324 /pubmed\" target=\"_blank\" id=\"11095324 \">11095324 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balaban DH, Duckworth CW, and Peura DA, &quot;Nasogastric Omeprazole: Effects on Gastric pH in Critically Ill Patients,&quot; <i>Am J Gastroenterol</i>, 1997, 92(1):79-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8995942/pubmed\" target=\"_blank\" id=\"8995942\">8995942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Canani RB, Cirillo P, Roggero P, et al, &quot;Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children,&quot; <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16651285/pubmed\" target=\"_blank\" id=\"16651285\">16651285</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chey WD, Wong BC, et al, &ldquo;American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection,&rdquo; <i>Am J Gastroent</i>, 2007, 102(8):1808-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/17608775/pubmed\" target=\"_blank\" id=\"17608775\">17608775</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diav-Citrin O, Arnon J, Shechtman S, et al, &quot;The Safety of Proton Pump Inhibitors in Pregnancy: A Multicentre Prospective Controlled Study,&quot; <i>Aliment Pharmacol Ther</i>, 2005, 21(3):269-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/15691301/pubmed\" target=\"_blank\" id=\"15691301\">15691301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Erichsen R, Mikkelsen E, Pedersen L, et al, &quot;Maternal Use of Proton Pump Inhibitors During Early Pregnancy and the Prevalence of Hypospadias in Male Offspring,&quot; <i>Am J Ther</i>, 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22314213/pubmed\" target=\"_blank\" id=\"22314213\">22314213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibbons TE and Gold BD, &quot;The Use of Proton Pump Inhibitors in Children: A Comprehensive Review,&quot; <i>Paediatr Drugs</i>, 2003, 5(1):25-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/12513104/pubmed\" target=\"_blank\" id=\"12513104\">12513104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gold BD, Colletti RB, Abbott M, et al, &quot;<i>Helicobacter pylori</i> Infection in Children: Recommendations for Diagnosis and Treatment,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2000, 31(5):490-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11144432/pubmed\" target=\"_blank\" id=\"11144432\">11144432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gottrand F, Kalach N, Spyckerelle C, et al, &quot;Omeprazole Combined With Amoxicillin and Clarithromycin in the Eradication of <i>Helicobacter pylori</i> in Children With Gastritis: A Prospective Randomized Double-Blind Trial,&quot; <i>J Pediatr</i>, 2001, 139(5):664-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11713443/pubmed\" target=\"_blank\" id=\"11713443\">11713443</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gunasekaran TS and Hassall EG, &quot;Efficacy and Safety of Omeprazole for Severe Gastroesophageal Reflux in Children,&quot; <i>J Pediatr</i>, 1993, 123(1):148-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/ 8320610 /pubmed\" target=\"_blank\" id=\" 8320610 \"> 8320610 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hassall E, Israel D, Shepherd R, &quot;Omeprazole for Treatment of Chronic Erosive Esophagitis in Children: A Multicenter Study of Efficacy, Safety, Tolerability and Dose Requirements. International Pediatric Omeprazole Study Group,&quot; <i>J Pediatr</i>, 2000, 137(6):800-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11113836/pubmed\" target=\"_blank\" id=\"11113836\">11113836</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n BA, &quot;Use of Omeprazole During Pregnancy-No Hazard Demonstrated in 955 Infants Exposed During Pregnancy,&quot; <i>Eur J Obstet Gynecol Reprod Biol</i>, 2001, 96(1):63-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11311763/pubmed\" target=\"_blank\" id=\"11311763\">11311763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kane DL, &quot;Administration of Omeprazole (Prilosec&trade;) in the Atypical Patient,&quot; <i>Int J Pharm Compounding</i>, 1997, 1(1):13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kato S, Ebina K, Fujii K, et al, &quot;Effect of Omeprazole in the Treatment of Refractory Acid-Related Diseases in Childhood: Endoscopic Healing and Twenty-Four Hour Intragastric Acidity,&quot; <i>J Pediatr</i>, 1996, 128(3):415-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8774516 /pubmed\" target=\"_blank\" id=\"8774516 \">8774516 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Katz PO, Gerson LB, and Vela MF, &quot;Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease,&quot; <i>Am J Gastroenterol</i>, 2013, 108(3):308-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23419381/pubmed\" target=\"_blank\" id=\"23419381\">23419381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaufman SS, Lyden ER, Brown CR, et al, &quot;Omeprazole Therapy in Pediatric Patients After Liver and Intestinal Transplantation,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2002, 34(2):194-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11840039/pubmed\" target=\"_blank\" id=\"11840039\">11840039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al, &quot;Evidence-Based Guidelines From ESPGHAN and NASPGHAN for <i>Helicobacter pylori</i> Infection in Children,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2011, 53(2):230-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21558964/pubmed\" target=\"_blank\" id=\"21558964\">21558964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lalkin A, Loebstein R, Addis A, et al, &quot;The Safety of Omeprazole During Pregnancy: A Multicenter Prospective Controlled Study,&quot; <i>Am J Obstet Gynecol</i>, 1998, 179(3 Pt 1):727-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9757979/pubmed\" target=\"_blank\" id=\"9757979\">9757979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2422.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24327038/pubmed\" target=\"_blank\" id=\"24327038\">24327038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, Bates ER, Blankenship JC, et al, &quot;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&quot; <i>Circulation</i>, 2011, 124(23):e574-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22064601/pubmed\" target=\"_blank\" id=\"22064601\">22064601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lightdale JR, Gremse DA, and the Section on Gastroenterology, Hepatology, and Nutrition,&quot; Gastroesophageal Reflux: Management Guidance for the Pediatrician,&quot; <i>Pediatrics</i>, 2013, 131(5):e1684-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23629618/pubmed\" target=\"_blank\" id=\"23629618\">23629618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marshall JK, Thompson AB, and Armstrong D, &quot;Omeprazole for Refractory Gastroesophageal Reflux Disease During Pregnancy and Lactation,&quot; <i>Can J Gastroenterol</i>, 1998, 12(3):225-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9582548/pubmed\" target=\"_blank\" id=\"9582548\">9582548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matok I, Levy A, Wiznitzer A, et al, &quot;The Safety of Fetal Exposure to Proton-Pump Inhibitors During Pregnancy,&quot; <i>Dig Dis Sci</i>, 2012, 57(3):699-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22038541/pubmed\" target=\"_blank\" id=\"22038541\">22038541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Omari TI, Haslam RR, Lundborg P, et al, &quot;Effect of Omeprazole on Acid Gastroesophageal Reflux and Gastric Acidity in Preterm Infants With Pathological Acid Reflux,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2007, 44(1):41-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/17204951/pubmed\" target=\"_blank\" id=\"17204951\">17204951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B and Hviid A, &quot;Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects,&quot; <i>N Engl J Med</i>, 2010, 363(22):2114-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21105793/pubmed\" target=\"_blank\" id=\"21105793\">21105793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prilosec capsules (omeprazole) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Song JC, Quercia RA, Fan C, et al, &quot;Pharmacokinetic Comparison of Omeprazole Capsules and a Simplified Omeprazole Suspension,&quot; <i>Am J Health Syst Pharm</i>, 2001, 58(8):689-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11329761/pubmed\" target=\"_blank\" id=\"11329761\">11329761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zimmermann AE, Walters JK, Katona BG, et al, &quot;A Review of Omeprazole Use in the Treatment of Acid-Related Disorders in Children,&quot; <i>Clin Ther</i>, 2001, 23(5):660-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11394727/pubmed\" target=\"_blank\" id=\"11394727\">11394727</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12658 Version 264.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50836889\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203557\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F203558\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060710\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F27749095\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060704\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203531\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F203517\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F45040042\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F15241703\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060713\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F203552\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060712\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203615\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203613\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203539\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203521\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F203601\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203526\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F203553\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F203542\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203520\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F203538\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F203537\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F203541\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F203544\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12658|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=omeprazole-drug-information\" class=\"drug drug_general\">Omeprazole: Drug information</a></li><li><a href=\"topic.htm?path=omeprazole-patient-drug-information\" class=\"drug drug_patient\">Omeprazole: Patient drug information</a></li></ul></div></div>","javascript":null}